Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Elevated neutrophil-to-lymphocyte ratio linked to depression and suicide risk

6

Jan 2026

Elevated neutrophil-to-lymphocyte ratio linked to depression and suicide risk

An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with increased risk of depressive disorder (DD) and may also correlate with suicide risk among individuals with DD, according to a systematic review and meta-analysis published in the November issue of Harvard Review of Psychiatry, part of the Lippincott portfolio from Wolters Kluwer.

Unveiling genetic links between schizophrenia and osteoporosis

6

Jan 2026

Unveiling genetic links between schizophrenia and osteoporosis

A comprehensive genetic investigation led by Dr. Feng Liu at Tianjin Medical University General Hospital has uncovered striking molecular connections between schizophrenia and bone health, identifying 195 shared genetic loci that may explain why psychiatric patients face elevated fracture risks.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.